Slightly Delayed, But It Seems Pfizer Decided Q3 2024 Was No Time To Lobby -- With Congressional Campaigning In Full Swing...

We will have to see how Q4 2024 turns out, but Pfizer radically cut its lobby-spending in Q3, compared to last year -- and even compared to its rough-peer-groups, in multinational pharma size. It dropped to about where the heavier spenders on the second tier of life science companies play -- and spent only about a third of whay Amgen spent.

Me? I think the Manhattan HQ-ed company realized no one was "listening" -- during the campaign rallies, nation-wide -- to what big pharma had on its wish list. But here is what Pfizer's much smaller outlay was spent on. We will do Merck tomorrow, and then Lilly, Amgen and the rest. [As ever, Amazon was about 4X, of these players.]

. . .VICP Reform and Excise Tax; Inflation Reduction Act (IRA); HR7174 - Ensuring Pathways to Innovative Cures (EPIC) Act; Medicare Price Setting; Part D Payer Utilization Management; Drug Shortages; S2916 - Prescription Information Modernization Act of 2023; Vaccines, Clinical Trials and Coverage; S2305 - Biosimilar Red Tape Elimination Act; Biosimilar Access and Interchangeability; HR 2666 - Medicaid Value Based Payments for Patients (MVP) Act; HR 4758 - Accelerating Kids Access to Care Act; HR 7384 - Rare Pediatric Disease Priority Review (PRV) Voucher; Trade-Related Aspects of Intellectual Property Rights; March-in Framework Guidance and Policies; S.79 - Interagency Patent Coordination and Improvement Act of 2023; S.142 - Preserve Access to Affordable Generics and Biosimilars Act; S.150 - Affordable Prescriptions for Patients Act of 2023; S.2780 - Medication Affordability and Patent Integrity Act; Digital: Data Flows and Digital Trade. . . .

S723/HR1458 - Access to Prescription Digital Therapeutics Act; HR8816 - American Medical Innovation and Investment Act of 2024; PBM Transparency and Reform; S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act; HR2880 - Protecting Patients Against PBM Abuses Act; HR5378 - Lower Costs More Transparency Act; 340B Reform; HR8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net (ACCESS) Act. . . .

Comprehensive Corporate Tax Reform; Tax Cuts and Jobs Act (TCJA); VICP Reform and Excise Tax; VICP Transition; Comprehensive Federal Tax Reform. . . .

International Supply Chain; HR4307/S2115 - Medical Supply Chain Resiliency Act. . . .

Now you know, and given the tumult we've seen this week -- it is likely that a hung Congress will mean not a lot of Tangerine's agenda (whatever that might entain for pharma) will ever come to pass. Again -- two years. . . or, four years. . . of inertia (most likely -- without even "concepts" of a plan). Y I K E S.

नमस्ते